2-chloro-4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-N-methylbenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2-chloro-4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-N-methylbenzamide
• 化学式: C₂₁H₁₅ClF₃N₅O₂S
• 分子量: 493.9
• InChiKey: UUSJGBMYGUSLHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• ANTI-ANDROGENS IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP3610876A1

  公开（公告）日：2020-02-19

  Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.

  本文描述的是式 (I) 的雄激素受体调节剂 与其他治疗方案联合治疗前列腺癌，以及治疗适合使用该雄激素受体调节剂治疗的疾病或病症，以及包括该化合物的药物组合物和药物。
• ANDROGEN RECEPTOR MODULATOR AND USES THEREOF
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP2945628A1

  公开（公告）日：2015-11-25
• ANDROGEN RECEPTOR MODULATOR IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP2945628B1

  公开（公告）日：2020-04-15
• Androgen Receptor Modulator And Uses Thereof
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：US20210177821A1

  公开（公告）日：2021-06-17

  Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.
• US9340524B2
  申请人：——

  公开号：US9340524B2

  公开（公告）日：2016-05-17